| Document |
Document Title |
|
WO/2022/042666A1 |
Provided are a ROCK2 kinase inhibitor as represented by general formula (I) and the use thereof in the preparation of a drug for preventing and/or treating ROCK2-related disorders. The compound is a highly efficient selective ROCK2 kinas...
|
|
WO/2022/040180A1 |
The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
|
|
WO/2022/038116A1 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of a disorder selected from autoimmune disorders, mental disorders, neurodegenerative disorders, pain, respiratory diseases...
|
|
WO/2022/038457A1 |
A precipitation process for amorphous Letermovir, contains residual solvents in accordance with ICH guidelines and is suitable for the preparation of orally administered pharmaceutical formulations. The formulations of the amorphous Lete...
|
|
WO/2022/037585A1 |
It relates to pyrimidinone compounds and uses thereof. In particular, it relates to pyrimidinone compounds of formula (I), and the pharmaceutical compositions, the preparing methods and the uses thereof, wherein the variables are as defi...
|
|
WO/2022/037704A1 |
A prodrug of a water-soluble anti-tumor drug, and a pharmaceutical composition and use of the prodrug. The anti-tumor drug is prepared by derivatizing an active compound having cytotoxicity and a high-polarity water-soluble micromolecule...
|
|
WO/2022/036312A2 |
The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.
|
|
WO/2022/032927A1 |
Disclosed in the present invention are a compound 1,1,3,3-tetramethyl guanidine(R)-(tert-butylcarbonyl)(2-(5-(2-fluoro-3-methoxyph
enyl)-3-(2-fluoro-6 (trifluoromethyl)phenmethyl)-4-methyl-2,6-dicarbonyl-3,6-dih
ydropyrimidine-1(2H)-yl) ...
|
|
WO/2022/033569A1 |
The present invention relates to crystal forms of benzamide compounds and a preparation method therefor. Provided are a crystal form J and an amorphous form of a compound of formula (I), and a preparation method and use thereof. The prov...
|
|
WO/2022/036313A1 |
The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.
|
|
WO/2022/032879A1 |
Provided is a photochemical synthesis method for a heteroaryl amine compound. The photochemical synthesis method comprises: step S1, mixing raw materials comprising a heteroaryl nitro compound, a solvent, and a photocatalyst to obtain a ...
|
|
WO/2022/033410A1 |
An EGFR inhibitor having the structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use of same as an EGFR inhibitor, and a use of same in preparing a drug for treating and/or preventing ...
|
|
WO/2022/036310A2 |
The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.
|
|
WO/2022/029795A1 |
The present invention relates to a process for the preparation of Lapatinib Ditosylate of formula 1(b). More particularly, the present invention relates to environment friendly process that involves green chemistry in preparation of Lapa...
|
|
WO/2022/031159A1 |
The present invention relates to a method for obtaining a new pyrimethamine polymorph, characterised in an intermediate a-(4-chlorophenyl)-2-ethyl-1,3-dioxalon-2-acetonitronyl is obtained by means of a reaction with ethylene glycol, and ...
|
|
WO/2022/029656A1 |
The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitr
ile (compound I). The present disclosure further provides methods for treating ocular surface pain by administeri...
|
|
WO/2022/027992A1 |
Provided are a nitrogen-containing compound, an electronic element, and an electronic device, and the present application belongs to the technical field of organic materials. In the nitrogen-containing compound, the 1-adamantyl and nitri...
|
|
WO/2022/031946A1 |
Provided herein are compounds of Formula I and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2022/028547A1 |
Provided in the present invention are a class of bifunctional compounds for targeting and degrading an IRAK4 kinase protein, a pharmaceutical composition and a preparation method therefor. The compound of the present invention can not on...
|
|
WO/2022/029154A1 |
The present invention relates to a process for the production of 2,2,4,6,6-pentamethyl-1,2,5,6-tetrahydro-pyrimidine comprising (i) providing a reactor containing a catalyst comprising a zeolitic material, wherein the zeolitic material c...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/026442A1 |
A method of treating NSCLC in a subject is provided. The method generally includes administering a therapeutically effective amount of poziotinib or a pharmaceutically acceptable salt thereof to a subject in need thereof. Poziotinib exhi...
|
|
WO/2022/020730A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/018625A1 |
Disclosed is an enantioselective process for the preparation of letermovir of formula (I) which comprises enantioselective addition of (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)ethanone (IV), catalysed by TiCl4 on the imine of formula III...
|
|
WO/2022/013081A1 |
The present invention relates to particles of a compound of formula M (I), wherein M is selected from Ni, Pd and Pt, X1 and X2 are each independently of each other sulfur or oxygen, R1, R2, R3, and R4 are independently selected from an u...
|
|
WO/2022/014433A1 |
The present invention pertains to: a compound represented by formula (I) (in the formula, R1 represents a hydroxyl group, a mercapto group, a C1-6-alkoxy group, a C1-6-haloalkoxy group, an amino group, a C1-6-alkyl amino group, or a di-C...
|
|
WO/2022/008639A1 |
The application relates to 2-imino-hexahydropyrimidin-4-one derivatives of formula (I) which are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful for the treatment of ma...
|
|
WO/2022/005881A1 |
Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions.
|
|
WO/2022/003712A1 |
The present invention described herein relates to a compound having Structure I for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in...
|
|
WO/2022/002116A1 |
The present invention provides a synthesis method for a phenylisoxazoline compound, comprising: synthesizing uracil first by taking 2-fluoro-4-chloro-5-methylaniline as a starting raw material, and then synthesizing an isoxazoline ring t...
|
|
WO/2022/002102A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of u...
|
|
WO/2021/260090A1 |
The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical com...
|
|
WO/2021/259815A1 |
The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufac...
|
|
WO/2021/223650A9 |
The present application relates to a nitrogen-containing compound. The structural formula of the nitrogen-containing compound is as shown in formula I, in which ring A and ring B are each independently selected from a benzene ring or a f...
|
|
WO/2021/256883A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound according to the present invention can be used in an organic material layer of an organic electroluminescent device,...
|
|
WO/2021/256881A1 |
The present invention relates to a novel compound having excellent light-emitting ability and an organic electroluminescent device comprising same, in which the compound according to the present invention is used in organic material laye...
|
|
WO/2021/254464A1 |
A substituted quinazoline compound, and a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a substituted quinazoline compound having BRK and/or BTK kinas...
|
|
WO/2021/256871A1 |
The present invention relates to a novel compound exhibiting excellent light-emitting performance and an organic electroluminescent device comprising same. The compound according to the present invention is used in an organic layer of an...
|
|
WO/2021/254920A1 |
Provided herein is a process for synthesis of intermediates for ipatasertib related to large scale manufacture of (R)-5-methyl-4-(piperazin-1-yl)-5,6-dihydro-7H-cyclopenta[d]
pyrimidin-7-one.
|
|
WO/2021/256880A1 |
The present invention relates to a novel compound having excellent light-emitting ability and an organic electroluminescent device comprising same. The compound according to the present invention can be used for the material of an organi...
|
|
WO/2021/255429A1 |
The invention includes a process for the synthesis of N,N-dimethyl-4-((6-oxopyrimidin-1(6H)- yl)methyl)benzamide and 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, a process for 5 synthesising crystalline forms of N,N-dimethyl-4-((6-ox...
|
|
WO/2021/255436A1 |
• A composition comprising 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid, • 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid for use as a medicament, • 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid for use in a method of trea...
|
|
WO/2021/250558A1 |
The invention provides an improved process for the preparation of fluoxastrobin and intermediates thereof. The present invention provides a process for the preparation of fluoaxastrobin, 4,6-dichloro-5-fluoro-pyrimidine and diethyl 2-chl...
|
|
WO/2021/250521A1 |
Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-as...
|
|
WO/2021/252680A1 |
Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating dis...
|
|
WO/2021/252475A1 |
Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods ...
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/244560A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...
|
|
WO/2021/244582A1 |
The present application provides a novel thyroid hormone β receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the β receptor ago...
|
